With the start of NUM 3.0, NUKLEUS (NUM Clinical Epidemiology and Study Platform) is also entering the next funding period. The Reseach Infrastructure in the Network University Medicine (NUM) supports researchers in the planning, implementation and evaluation of large-scale clinical and epidemiological studies conducted within the framework of NUM.
Since 1 July 2025, the platform has had a new team of spokespersons: Prof. Dr Maria Vehreschild (University Medicine Frankfurt), Prof. Dr Dagmar Krefting (University Medicine Göttingen), Prof. Dr Wolfgang Hoffmann (University Medicine Greifswald) and Dr Markus Wolfien (Technical University Dresden) will give NUKLEUS its voice in future.
NUKLEUS 3.0 also gives the platform a new structure: two new work packages complement the infrastructure - the "Adaptive Platform Trial Support Unit" (APT_SU) and the unit for data acceptance and processing of external data (DAAeD). The APT_SU supports scientists in planning and implementing adaptive platform studies. For example, in the selection of suitable APT models, associated sponsor activities, study designs, case number planning, statistics or templates for informed consent. The DAAeD integrates external data sources, for example from health insurance companies, reporting and cancer registries.
At the same time, the biospecimen core, the epidemiology core and ethics coordination will be bundled in the newly established cross-sectional area(QS-MB). NUKLEUS will work closely with the new cross-sectional area.
In the area of image and biosignal data, NUKLEUS will also cooperate closely with the RACOON infrastructure in the new funding phase. We look forward to continuing our trusting collaboration with all partners!